FDA Rejects Biosimilar Naming Petitions from GPhA, Sandoz; Approves J&J’s

The FDA rejected two citizen petitions urging the agency to allow biosimilar sponsors to use the same nonproprietary names as their reference products, finding them incompatible with final guidance on the agency’s naming scheme published earlier this month.
Source: Drug Industry Daily